about
microRNAs as pharmacogenomic biomarkers for drug efficacy and drug safety assessmentMicroRNAs in Drug-induced Liver InjuryBack to the future: transgenerational transmission of xenobiotic-induced epigenetic remodelingMicroRNA-21-3p, a berberine-induced miRNA, directly down-regulates human methionine adenosyltransferases 2A and 2B and inhibits hepatoma cell growthPharmacogenetics of microRNAs and microRNAs biogenesis machinery in pediatric acute lymphoblastic leukemiaMicroRNAs in liver diseaseRapid production of novel pre-microRNA agent hsa-mir-27b in Escherichia coli using recombinant RNA technology for functional studies in mammalian cells.microRNA-34a is associated with expression of key hepatic transcription factors and cytochromes P450Suppression of CYP2C9 by microRNA hsa-miR-128-3p in human liver cells and association with hepatocellular carcinoma.Identification of microRNAs and their response to the stress of plant allelochemicals in Aphis gossypii (Hemiptera: Aphididae).MicroRNA Pharmacoepigenetics: Posttranscriptional Regulation Mechanisms behind Variable Drug Disposition and Strategy to Develop More Effective TherapySmall nucleolar RNA-derived microRNA hsa-miR-1291 modulates cellular drug disposition through direct targeting of ABC transporter ABCC1Potential role of epigenetic mechanisms in the regulation of drug metabolism and transport.BDE47 induces rat CYP3A1 by targeting the transcriptional regulation of miR-23b.Network-based identification of microRNAs as potential pharmacogenomic biomarkers for anticancer drugs.Epigenetic regulation of ADME-related genes: focus on drug metabolism and transport.Systems approaches in risk assessment.Hopes and challenges in using miRNAs as translational biomarkers for drug-induced liver injury.Importance of ABCC1 for cancer therapy and prognosis.MicroRNAs as key regulators of xenobiotic biotransformation and drug response.The role of microRNAs in toxicology.The role for microRNAs in drug toxicity and in safety assessment.MicroRNA hsa-miR-25-3p suppresses the expression and drug induction of CYP2B6 in human hepatocytes.MicroRNA hsa-miR-29a-3p modulates CYP2C19 in human liver cells.MiRNAs-mediated cisplatin resistance in breast cancer.Effects of MicroRNA-34a on the Pharmacokinetics of Cytochrome P450 Probe Drugs in Mice.MiR-218 regulates cisplatin chemosensitivity in breast cancer by targeting BRCA1.MicroRNA-targeted therapeutics for lung cancer treatment.Molecular Pathways: GLI1-Induced Drug Glucuronidation in Resistant Cancer Cells.Neuronal developmental gene and miRNA signatures induced by histone deacetylase inhibitors in human embryonic stem cells.Digging up the human genome: current progress in deciphering adverse drug reactions.In vitro evidence for bakuchiol's influence towards drug metabolism through inhibition of UDP-glucuronosyltransferase (UGT) 2B7.MicroRNAs and toxicology: A love marriage.Modulation of ALDH5A1 and SLC22A7 by microRNA hsa-miR-29a-3p in human liver cells.Modern methodologies and tools for human hazard assessment of chemicals
P2860
Q26778918-FC88C2F4-1DA4-4529-91C1-AA19BCBA0EBBQ26781801-BA212DDA-AAF4-4B4D-9429-E6344FC68676Q26852391-CF58474E-B3B4-48BD-8DE9-D94E9EB50CD8Q28533929-EA6AD799-B3CB-428F-A8D0-2EF35E0020D3Q28540685-A833EE31-B767-4D5C-894F-E1336D61F1EFQ33880442-B0CB9C58-3AED-4E48-BE21-3AA9233DA554Q34360047-594661EF-9750-4523-B305-1BF7B1E49F9CQ35063942-0AEE574F-9E10-4474-943D-EAE0CA2CBE12Q35109229-1CB2AD24-90F5-404C-86B1-C453A78ACE4DQ36281736-1B5F2A2A-4DF6-48FB-8F48-D3DA9DB4F7F5Q36618667-DB8A12A9-6E4A-45F5-9BBC-98FFB568CF57Q37193077-6A2B4A2F-4519-4563-9B23-906432A6D43FQ37193085-0A416F2B-728D-4B91-A230-80A8F11850F0Q37193395-30948D81-6CAA-4E93-A017-CCB6DEFEAE1CQ37564492-CF0BA8AA-28F0-4414-B252-EC14621B553BQ37576018-2AA8170D-98EF-48C2-896C-610D7323AD59Q38093360-786C8690-71C1-419A-B507-2D96062A9F3BQ38095111-1C4B0D17-2AE6-4A2B-80F3-9525E04445B4Q38199535-563BB050-98EB-45E7-966A-A3A27AB61A0CQ38235604-A52B663B-C295-46D5-99BC-9AB50BC7F365Q38317697-0DFC1305-89AF-4D8E-B5B9-7F765D481D30Q38367620-D475B37A-0B22-478C-8038-C9BF515FD0B4Q38764044-3C5DAB19-14AF-448E-ADAA-B9308D8E6786Q38841918-D27F76C6-C06A-4A14-BCBA-B2E781E5EFB2Q38905681-08B0B187-D513-4E29-B60F-6B83A10D2F15Q38932270-D8D2C162-63E9-4282-8A56-AA29B33395B4Q38940572-3D01264E-06F5-45F7-8682-5F244D3DEF44Q39014580-A2FB6DAA-746D-4BFD-B12B-53CAB1DA237CQ40732028-6D2E8CA5-0E32-48D3-BEBF-992BD4F90338Q40965816-9FB96114-3BCC-4829-A418-B3A709714B6CQ41889353-0158BA0E-3398-4EB3-8236-C62A25D36488Q42961853-0749921D-5D34-4648-8578-5A15C04BA563Q45352157-D748C108-7ECE-4E80-9588-00A03762FCD9Q47141339-2B8E12EA-90E7-4A80-BA36-94D8065C197EQ47154406-9CB43E21-2221-4E20-86EB-FE8606F37F4C
P2860
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
microRNAs as mediators of drug toxicity.
@en
type
label
microRNAs as mediators of drug toxicity.
@en
prefLabel
microRNAs as mediators of drug toxicity.
@en
P1476
microRNAs as mediators of drug toxicity.
@en
P2093
Miki Nakajima
Tsuyoshi Yokoi
P304
P356
10.1146/ANNUREV-PHARMTOX-011112-140250
P577
2012-11-16T00:00:00Z